COMMUNIQUÉS West-GlobeNewswire

Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
09/08/2019
NORCROSS, Ga., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
09/08/2019
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac ® , trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019 ASCO presentation [...]
Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
09/08/2019
LAVAL, Québec, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of [...]
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction
09/08/2019
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated [...]
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
09/08/2019
LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a [...]
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
09/08/2019
Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and [...]
Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
09/08/2019
Recorded First Revenues for AZEDRA ® ; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL TM [...]
TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
09/08/2019
Conference call to be held today, Friday, August 9, 2019 at 8:30 AM ET NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended [...]
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
09/08/2019
~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ~ Commenced Enrollment in [...]
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results
09/08/2019
CANTON, Mass., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
09/08/2019
THE WOODLANDS, Texas, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief [...]
Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
09/08/2019
Gained worldwide rights to VY-HTT01 for Huntington’s disease, expanding wholly-owned pipeline Presented additional Phase 1b results for VY-AADC in patients with Parkinson’s disease at the 2019 American Academy of [...]
Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019
09/08/2019
SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019 Data from patients dosed with AXO-AAV-GM1 and [...]
ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update
09/08/2019
YONKERS, N.Y., Aug. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and [...]
Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update
09/08/2019
Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other cost reduction actions on track to realize $80 to $90 million in annualized cost savings REST-ON 69% enrolled; 81 [...]
PLx Pharma Inc. Reports Second Quarter 2019 Results
09/08/2019
--Company completes manufacture of registration batches; remains on track for sNDA submission by year-end-- SPARTA, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late [...]
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
09/08/2019
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Fennec [...]
ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action
09/08/2019
LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuant to an Order of the [...]
Periodic update on transaction details related to Philips’ share repurchases
09/08/2019
August 9, 2019 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today reported that in the period from August 2, 2019 up to and including August 8, 2019 a total of 570,565 of its own common shares were [...]

Pages